Eledon Pharmaceuticals Reports Expanded Net Loss for FY 2025 and Operational Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy ELDN?
Source: NASDAQ.COM
- Financial Overview: Eledon Pharmaceuticals reported an expanded net loss of $45.6 million for FY 2025, translating to a loss of $0.52 per share, compared to $36.2 million and $0.66 per share in the previous year, indicating ongoing pressures in R&D and operations that may affect future funding capabilities.
- Drug Development Progress: The lead candidate Tegoprubart received Orphan Drug designation from the FDA for liver transplantation, and 24-month follow-up data from eight patients was presented at the American Society of Transplant Surgeons Winter Symposium, further supporting its safety and tolerability profile with no reported adverse events, enhancing market confidence.
- Diabetes Patient Trial Results: In a study involving 12 patients with type 1 diabetes, 10 patients achieved 100% insulin independence after more than four weeks, with the latest hemoglobin A1c (HbA1c) levels below 6.0% and an average HbA1c of approximately 5.35%, demonstrating Tegoprubart's potential in immunosuppressive therapy and generating inquiries from several hundred patients.
- Expected Future Milestones: The company anticipates receiving FDA guidance on the Phase 3 trial design for Tegoprubart in kidney transplantation, with plans to initiate the trial pending regulatory alignment, and will report long-term data from Phase 1 and Phase 2 BESTOW studies, reflecting a proactive approach to advancing product commercialization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELDN
Wall Street analysts forecast ELDN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.000
Low
4.00
Averages
7.75
High
10.00
Current: 3.000
Low
4.00
Averages
7.75
High
10.00
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eledon Pharmaceuticals Reports Expanded Net Loss for FY 2025 and Operational Updates
- Financial Overview: Eledon Pharmaceuticals reported an expanded net loss of $45.6 million for FY 2025, translating to a loss of $0.52 per share, compared to $36.2 million and $0.66 per share in the previous year, indicating ongoing pressures in R&D and operations that may affect future funding capabilities.
- Drug Development Progress: The lead candidate Tegoprubart received Orphan Drug designation from the FDA for liver transplantation, and 24-month follow-up data from eight patients was presented at the American Society of Transplant Surgeons Winter Symposium, further supporting its safety and tolerability profile with no reported adverse events, enhancing market confidence.
- Diabetes Patient Trial Results: In a study involving 12 patients with type 1 diabetes, 10 patients achieved 100% insulin independence after more than four weeks, with the latest hemoglobin A1c (HbA1c) levels below 6.0% and an average HbA1c of approximately 5.35%, demonstrating Tegoprubart's potential in immunosuppressive therapy and generating inquiries from several hundred patients.
- Expected Future Milestones: The company anticipates receiving FDA guidance on the Phase 3 trial design for Tegoprubart in kidney transplantation, with plans to initiate the trial pending regulatory alignment, and will report long-term data from Phase 1 and Phase 2 BESTOW studies, reflecting a proactive approach to advancing product commercialization.
See More
Eledon Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Highlights: Eledon Pharmaceuticals reported a FY 2025 GAAP EPS of -$0.52, beating expectations by $0.15, indicating a positive trend in improving profitability despite still being in a loss position.
- Cash Position: As of FY 2025, Eledon's cash, cash equivalents, and short-term investments totaled $133.33 million, down from $140.18 million in FY 2024, reflecting challenges in financial management and operational expenditures.
- Product Development: Eledon's lead asset, Tegoprubart, received FDA orphan drug status, highlighting its potential in the immunosuppressive market and possibly providing new revenue growth opportunities for the company.
- Market Reaction: Eledon Pharmaceuticals' stock rose due to the earnings beat and FDA approval news, indicating increased investor confidence in the company's future, which may attract more attention from investors regarding its long-term growth potential.
See More
Eledon Pharmaceuticals Reports Positive Data on Tegopribart for Type 1 Diabetes
- Clinical Trial Results: In a cohort of 12 patients undergoing allogeneic islet transplantation for type 1 diabetes, 10 achieved 100% insulin independence four weeks post-transplant, demonstrating significant efficacy that could reshape diabetes treatment paradigms.
- Immunosuppressive Advantage: Tegopribart, an anti-CD40L monoclonal antibody, showed no signs of graft rejection or de novo donor-specific human leukocyte antigen antibodies, indicating its potential as a safer treatment option for patients requiring immunosuppression.
- Market Outlook: With the FDA granting orphan drug status to Eledon Pharmaceuticals' lead asset, the company significantly enhances its market opportunities in diabetes treatment, likely attracting increased investor interest.
- Financial Performance: Historical earnings data for Eledon Pharmaceuticals suggests that as drug development progresses, the company's future revenue potential will substantially increase, further solidifying its position in the biopharmaceutical industry.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: Eledon Pharmaceuticals' lead candidate, tegoprubart, has received Orphan Drug designation from the FDA, which is expected to provide a crucial treatment option for preventing allograft rejection in liver transplantation, enhancing the company's competitive position in the biotech sector.
- Market Opportunity Assessment: CEO David-Alexandre Gros stated that based on encouraging preclinical evidence, liver transplantation represents a significant incremental market opportunity for tegoprubart, potentially driving future revenue growth for the company.
- Clinical Trial Plans: The company anticipates initiating an investigator-sponsored trial later this year to further validate the efficacy and safety of the antibody therapy, aiming to expedite the product's market entry.
- Regulatory Incentives: The FDA's Orphan Drug designation offers Eledon multiple regulatory advantages, including tax credits for clinical trial costs and waivers for marketing application user fees, along with up to seven years of U.S. marketing exclusivity, significantly enhancing the company's commercial outlook.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation for Tegoprubart
- Orphan Drug Designation: Eledon Pharmaceuticals announced that its drug tegoprubart has received FDA orphan drug designation aimed at preventing allograft rejection in liver transplantation, which opens new market opportunities for the company in this critical area.
- Clinical Trial Plans: CEO David-Alexandre Gros stated that based on the encouraging preclinical evidence generated so far, Eledon plans to initiate an investigator-sponsored clinical trial later this year to evaluate the potential of tegoprubart in liver transplantation.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Eledon shares rose by 6.9% to $3.1, reflecting a positive market sentiment regarding the drug's prospects, which may attract more investor interest.
- Multiple Designation Background: Notably, tegoprubart has previously received orphan drug designation for preventing allograft rejection in pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis, indicating its potential across multiple indications.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
Eledon Pharmaceuticals Reports Expanded Net Loss for FY 2025 and Operational Updates
- Financial Overview: Eledon Pharmaceuticals reported an expanded net loss of $45.6 million for FY 2025, translating to a loss of $0.52 per share, compared to $36.2 million and $0.66 per share in the previous year, indicating ongoing pressures in R&D and operations that may affect future funding capabilities.
- Drug Development Progress: The lead candidate Tegoprubart received Orphan Drug designation from the FDA for liver transplantation, and 24-month follow-up data from eight patients was presented at the American Society of Transplant Surgeons Winter Symposium, further supporting its safety and tolerability profile with no reported adverse events, enhancing market confidence.
- Diabetes Patient Trial Results: In a study involving 12 patients with type 1 diabetes, 10 patients achieved 100% insulin independence after more than four weeks, with the latest hemoglobin A1c (HbA1c) levels below 6.0% and an average HbA1c of approximately 5.35%, demonstrating Tegoprubart's potential in immunosuppressive therapy and generating inquiries from several hundred patients.
- Expected Future Milestones: The company anticipates receiving FDA guidance on the Phase 3 trial design for Tegoprubart in kidney transplantation, with plans to initiate the trial pending regulatory alignment, and will report long-term data from Phase 1 and Phase 2 BESTOW studies, reflecting a proactive approach to advancing product commercialization.
See More
Eledon Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Highlights: Eledon Pharmaceuticals reported a FY 2025 GAAP EPS of -$0.52, beating expectations by $0.15, indicating a positive trend in improving profitability despite still being in a loss position.
- Cash Position: As of FY 2025, Eledon's cash, cash equivalents, and short-term investments totaled $133.33 million, down from $140.18 million in FY 2024, reflecting challenges in financial management and operational expenditures.
- Product Development: Eledon's lead asset, Tegoprubart, received FDA orphan drug status, highlighting its potential in the immunosuppressive market and possibly providing new revenue growth opportunities for the company.
- Market Reaction: Eledon Pharmaceuticals' stock rose due to the earnings beat and FDA approval news, indicating increased investor confidence in the company's future, which may attract more attention from investors regarding its long-term growth potential.
See More
Eledon Pharmaceuticals Reports Positive Data on Tegopribart for Type 1 Diabetes
- Clinical Trial Results: In a cohort of 12 patients undergoing allogeneic islet transplantation for type 1 diabetes, 10 achieved 100% insulin independence four weeks post-transplant, demonstrating significant efficacy that could reshape diabetes treatment paradigms.
- Immunosuppressive Advantage: Tegopribart, an anti-CD40L monoclonal antibody, showed no signs of graft rejection or de novo donor-specific human leukocyte antigen antibodies, indicating its potential as a safer treatment option for patients requiring immunosuppression.
- Market Outlook: With the FDA granting orphan drug status to Eledon Pharmaceuticals' lead asset, the company significantly enhances its market opportunities in diabetes treatment, likely attracting increased investor interest.
- Financial Performance: Historical earnings data for Eledon Pharmaceuticals suggests that as drug development progresses, the company's future revenue potential will substantially increase, further solidifying its position in the biopharmaceutical industry.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation
- FDA Orphan Drug Designation: Eledon Pharmaceuticals' lead candidate, tegoprubart, has received Orphan Drug designation from the FDA, which is expected to provide a crucial treatment option for preventing allograft rejection in liver transplantation, enhancing the company's competitive position in the biotech sector.
- Market Opportunity Assessment: CEO David-Alexandre Gros stated that based on encouraging preclinical evidence, liver transplantation represents a significant incremental market opportunity for tegoprubart, potentially driving future revenue growth for the company.
- Clinical Trial Plans: The company anticipates initiating an investigator-sponsored trial later this year to further validate the efficacy and safety of the antibody therapy, aiming to expedite the product's market entry.
- Regulatory Incentives: The FDA's Orphan Drug designation offers Eledon multiple regulatory advantages, including tax credits for clinical trial costs and waivers for marketing application user fees, along with up to seven years of U.S. marketing exclusivity, significantly enhancing the company's commercial outlook.
See More
Eledon Pharmaceuticals Receives FDA Orphan Drug Designation for Tegoprubart
- Orphan Drug Designation: Eledon Pharmaceuticals announced that its drug tegoprubart has received FDA orphan drug designation aimed at preventing allograft rejection in liver transplantation, which opens new market opportunities for the company in this critical area.
- Clinical Trial Plans: CEO David-Alexandre Gros stated that based on the encouraging preclinical evidence generated so far, Eledon plans to initiate an investigator-sponsored clinical trial later this year to evaluate the potential of tegoprubart in liver transplantation.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Eledon shares rose by 6.9% to $3.1, reflecting a positive market sentiment regarding the drug's prospects, which may attract more investor interest.
- Multiple Designation Background: Notably, tegoprubart has previously received orphan drug designation for preventing allograft rejection in pancreatic islet cell transplantation and for treating amyotrophic lateral sclerosis, indicating its potential across multiple indications.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Collaborative Research Agreement: NewcelX has signed a collaborative research agreement with Eledon to integrate its lead product NCEL-101 with Eledon's anti-CD40L monoclonal antibody tegoprubart, aiming to advance a functional cure for Type 1 Diabetes, marking a significant advancement in diabetes treatment.
- Integration of Clinical Experience: Eledon's clinical experience with over 100 transplant patients will provide crucial clinical data and insights for the development of NCEL-101, potentially streamlining the regulatory pathway and accelerating the product's market entry.
- Enhanced Immune Modulation: The immune modulation component of NCEL-101 is designed to improve cell durability and graft survival, with expectations to match outcomes seen with donor human islets, thereby enhancing treatment efficacy and addressing market demand for functional insulin-producing cells.
- Strategic Milestone: NewcelX's Chief Scientific Officer stated that this collaboration not only enhances the company's clinical execution capabilities but also broadens partnerships with leaders in immune biology and transplant medicine, which is expected to accelerate clinical project advancement and increase visibility among investors.
See More
